Navigation Links
Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
Date:12/20/2007

BENSALEM, Pa., Aug. 10 /PRNewswire/ -- Law Offices of Howard G. Smith announces a September 4, 2007, deadline to move to be a lead plaintiff in the securities class action lawsuit filed on behalf of all purchasers of the common stock of Threshold Pharmaceuticals, Inc. ("Threshold Pharmaceuticals" or the "Company")(Nasdaq: THLD) between February 4, 2005 and July 14, 2006 (the "Class Period"), including purchasers in Threshold's February 4, 2005, initial public offering and its October 12, 2005, follow-on offering. The shareholder lawsuit is pending in the United States District Court for the Southern District of New York.

The Complaint alleges that defendants violated federal securities laws by issuing material misrepresentations to the market concerning the Company's business and prospects, thereby artificially inflating the price of Threshold Pharmaceuticals securities.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Threshold Pharmaceuticals securities during any of the periods, and/or pursuant to any of the offerings, described above, you have certain rights, and have 25 days remaining -- until September 4, 2007 -- in which to move for Lead Plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215)638-4847, Toll-Free at (888)638-4847, by email to howardsm
'/>"/>

SOURCE Law Offices of Howard G. Smith
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
2. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
3. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Micrus Endovascular Corporation
4. Demonstration at Carlyle Group Offices Monday as Grassroots Caravan of Caregivers, Senior Advocates Arrives in D.C. to Speak Out for Improved Care, Staffing at Nations Largest Nursing Home Chain
5. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against WellCare Health Plans, Inc.
6. Law Offices of Howard G. Smith Announces 14 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Care Investment Trust Inc.
7. Northern Fertility & Reproductive Associates Adds Two Local Infertility Specialists to Staff, Opens New Offices In Center City And Blue Bell
8. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Micrus Endovascular Corporation
9. Excerpts from DNC Chairman Howard Deans Remarks at the National Baptist Convention
10. UT Southwestern researcher named Howard Hughes Medical Institute investigator
11. CVS Caremarks Howard McLure Elected New PCMA Board Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...team develops device giving patients freedom of mo...DAY, July 26 (HealthDay News) -- An automated arti...e day be to dialysis patients what the insulin pum...rable artificial kidney (AWAK) works better than c...current issue of Clinical and Experimental Nephro...
(Date:7/25/2008)...AKE SUCCESS, N.Y., July 25 /PRNewswire-USNewswire/...as Chief Quality Officer and Vice President,of Str...monwealth Fund, a,national foundation committed to...e directed the foundation,s Program on Health Care...p://www.newscom.com/cgi-bin/prnh/20080725/DC28791L...
(Date:7/25/2008)...red immune response after antiretroviral therapy m... July 25 (HealthDay News) -- A new study challenge...(HCV) impairs the immune system,s ability to resto...ly active antiretroviral therapy (HAART). , Fro...ers are also infected with HCV. Intravenous drug u...
(Date:7/25/2008)...he Authority offers patients consumers tips and en...ient safety, HARRISBURG, Pa., July 25 /PRNewswire...thority today supports "National Patient Safety Da...s and their families to,participate fully in their...thing they can about their surgery or illness., "...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...ngton, in Seattle, a group of engineers has recent... latest creation: a surgical robot// to deploy in ... a remote control console. Military groups all ov... in remote surgery. On the battlefield, medical re...
...Children's Research Hospital have discovered that ...duction of a molecule that is key to the ability//...s to break down toxins, and of cells to extract en...estigators showed that ABCB6 is lodged within the ...
...ide rates among younger and older Americans have b...ling news: No one really knows why// . Those are ...t the University of South Carolina and released Th...tober issue of the American Journal of Public Heal...
...lty members performing microsurgery in Tanzania fr...om, or health care experts// in Vietnam presenting...thered in the Hopkins outpatient center. These are... Internet communication system that will be used f...
Other Medicine News:Health News:Doc at a Distance 2Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3Health News:High-Speed Internet2 Link Revolutionizes Global Medical Education 2
(Date:7/24/2008)... /PRNewswire-USNewswire/ -- Headlines claiming "so...e story. The small scale,preliminary study that D...duction, is based on recollected intake of soyfood...This study is confounded by many,issues, thus I fe...of,caution," warned Dr. Tammy Hedlund, a researche...
(Date:7/24/2008)...rance, July 24 /- NicOx S.A...ne results from the 52-week,open label safety exte...of,the 301 phase 3 study for naproxcinod. The resu...icacy was maintained for the one-year duration of,...essment scale. In,addition, the results showed tha...
(Date:7/23/2008)... /PRNewswire-USNewswire/ -- The following was,rele... Conyers, Ranking Member Smith, and Members of the...fy today., Since I appeared before this Committee...acquainted with the talented and dedicated profess... they do, and I have come to,appreciate that much ...
(Date:7/23/2008)...RNewswire-FirstCall/ -- Dendreon Corporation,(Nasd...dependent Data,Monitoring Committee (IDMC) to revi... survival relating to the Company,s Phase 3 IMPACT...ent, also known as D9902B) clinical trial,of PROVE...nvestigational,active cellular immunotherapy for t...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Steps toward Stopping Autoimmune Disease 1967 1Steps toward Stopping Autoimmune Disease 1967 2CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 1CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 2Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 1Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 2Solutions for Parents Who Need Cold Remedies for Their Children 9795 1Solutions for Parents Who Need Cold Remedies for Their Children 9795 2
...EGO, May 22, 2007 /PRNewswire/ -- A new study pres...iddle-of-the-night,balance, mobility or memory per...o placebo. This study also demonstrated, as in,pre... did have,impaired performances on these measures,...e-blind, placebo-controlled trial were,presented i...
... Release of Data for New Combination , , , , , P...cium channel blocker,amlodipine besylate with the ... produced significant mean reductions in,seated sy...th,hypertension, according to data presented at th...Second Annual Scientific Meeting and,Exposition (A...
Other Medicine Technology:New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 2New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 3New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 4Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 4
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments.
Liquichek Qualitative Urine Toxicology Control is a liquid control designed for use with qualitative rapid urine drug screen panels, including Point of Care (POC) Drugs of Abuse (DOA) test kits like
Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates.
Liquichek Hematology-16 Control is specifically designed for use on most hematology analyzers that measure up to 16 parameters and 3-part white blood cell differentials. This trilevel control can be
Medicine Products: